Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

onncology

- PMLiVE

Merck and Moderna to jointly develop personalised cancer vaccine in $250m deal

The vaccine is currently being evaluated as a treatment for high-risk melanoma patients

- PMLiVE

Merck KGaA announces launch of start-up collaboration programme in Asia

The selected companies will receive up to €100,000 in financial assistance, as well as mentoring from Merck

- PMLiVE

Merck KGaA to make $3m payout to patients after drug formulation complaints

La Cour de Cassation has ordered the company to make the payment to more than 3,000 patients to settle the reformulation dispute

- PMLiVE

Merck KGaA’s Glucophage approved in Europe as first oral diabetic medication for use during pregnancy

The oral drug offers comparable maternal blood sugar control to insulin, which needs to be injected

- PMLiVE

Imugene’s cancer vaccine shows promise in mid-stage stomach cancer trial

HER-Vaxx plus chemotherapy resulted in ORR of 50% compared to 29% for chemotherapy alone

- PMLiVE

Merck KGaA gains exclusive rights to Debiopharma’s late-stage oncology asset

Development and commercialisation deal could be worth up to $1.08bn

- PMLiVE

Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance

Bispecific antibody fails in non-small cell lung cancer trial

- PMLiVE

Merck KGaA signs deal with Artios Pharma potentially worth up to $860m

Three-year collaboration agreement will seek to develop a range of therapeutic candidates

- PMLiVE

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

Picks up approval as a first-line treatment for advanced cancer

- PMLiVE

Merck gets first approval for MET inhibitor tepotinib in Japan

First worldwide approval for MET inhibitor

- PMLiVE

Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer

Checkpoint inhibitor unlikely to improve progression-free survival

- PMLiVE

Merck KGaA divests allergy business to Dermapharm

The sum of the agreement remains undisclosed

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links